Lineage Cell Therapeutics (LCTX) Interest Coverage Ratio Growth (3y) (2014 - 2026)
Lineage Cell Therapeutics (LCTX) Interest Coverage Ratio Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -11.54% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 82.53% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 43.08% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 28.57% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -26.00% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -24.77% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 33.30% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 81.16% |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn | 0.68% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.68% |
| Mar 31, 2026 | 63.29% |
| Dec 31, 2025 | -0.71% |
| Sep 30, 2025 | 70.95% |
| Jun 30, 2025 | 56.07% |
| Mar 31, 2025 | 5.26% |
| Dec 31, 2024 | 47.21% |
| Sep 30, 2024 | 29.29% |
| Jun 30, 2024 | 19.25% |
| Mar 31, 2024 | 57.13% |
| Dec 31, 2023 | 32.76% |
| Sep 30, 2023 | -154.90% |
| Jun 30, 2023 | -110.12% |
| Mar 31, 2023 | -38.70% |
| Dec 31, 2022 | -0.68% |
| Sep 30, 2022 | -23.00% |
| Jun 30, 2022 | -110.98% |
| Mar 31, 2022 | -105.26% |
| Dec 31, 2021 | -657.07% |
| Dec 31, 2020 | -183.86% |